The Lancet Infectious Diseases
Apr 2014 Volume 14 Number 4 p257 – 358
http://www.thelancet.com/journals/laninf/issue/current
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial
Richard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, David M Asmuth, Barry Peters, Adriano Lazzarin, Felipe Garcia, Kim Ellefsen, Daniel Podzamczer, Jan van Lunzen, Keikawus Arastéh, Dirk Schürmann, Bonaventura Clotet, W David Hardy, Ronald Mitsuyasu, Graeme Moyle, Andreas Plettenberg, Martin Fisher, Gerd Fätkenheuer, Margaret Fischl, Babafemi Taiwo, Ingebjørg Baksaas, Darren Jolliffe, Stefan Persson, Øyvind Jelmert, Arnt-Ove Hovden, Maja A Sommerfelt, Vidar Wendel-Hansen, Birger Sørensen
Preview |
The proportion of participants resuming cART before end of study and change in CD4 counts during the treatment interruption showed no benefit of vaccination. Vacc-4x was safe, well tolerated, immunogenic, seemed to contribute to a viral-load setpoint reduction after cART interruption, and might be worth consideration in future HIV-cure investigative strategies.